Grainne O'Kane retweeted
Intrahepatics doing best with GBC and extra hepatic OS HR not as favourable; GBC definitely different biology, with HR similar to TOPAZ in this primary site; more research needed @CharityAMMF @PrecisionBTCnet @curecc
🔥HARMONi-GI1 ph3 advanced #BTC
➡️ivonescimab/GC v durva/GC mFU 14.3mths; China only & interim
✅ iCCA 58% ORR 53.8v32.5%; mPFS 8.4 v 5.8mths
✅mOS 14.9 v12.1mths HR0.75
➡️AE rate high in both
Control arm OS represents❗️VEGF in BTC ⭐️ looks promising
@myESMO #ESMO26 @OncoAlert
🔥HARMONi-GI1 ph3 advanced #BTC
➡️ivonescimab/GC v durva/GC mFU 14.3mths; China only & interim
✅ iCCA 58% ORR 53.8v32.5%; mPFS 8.4 v 5.8mths
✅mOS 14.9 v12.1mths HR0.75
➡️AE rate high in both
Control arm OS represents❗️VEGF in BTC ⭐️ looks promising
@myESMO #ESMO26 @OncoAlert
Masterful talk @BasGrootKoerkam on localised #PDAC & #BTC 🔑points👇
➡️PDAC staging requires anatomy/biology/clinical ass
➡️?older patients benefit NAC
➡️hilar obs➡️perc stenting TESLA
➡️high risk iCCA consider NAC
➡️LRT & Liver tx evolving in iCCA
@myESMO #ESMO26 @OncoAlert
GFH276 pan-RAS (ON) molecular glue
➡️ph1/1b data; n=73 PDAC ,5-320mg
➡️no . prior lines tx =2
➡️ORR 41% in #PDAC, @ 40-160mg,
small nos with prior RASi
➡️Rash most common AE
As many trials move quickly to 1st line, how will we sequence??
@myESMO #ESMO26 @OncoAlert
Grainne O'Kane retweeted
Today I had the honor to discuss two important abstracts of novel treatment approaches for patients with #HCC across different stages and settings at #ESMO26. Not yet in clinical practice, but clinically relevant results. #ESMOAmbassadors @myESMO @HUNIMED @HumanitasMilano
🔥Promising #HCC BGB-B2033
➡️GPC3 x 4-1BB bispecific ph1/2 more mature data
➡️dose escalation/optimisation
activity across all: 2/3rd >2 prior lines
ORR ~36%
➡️450mg selected R2PD; very favourable toxicity
➡️Phase 3 GroundBBreaker 301 due to open
@myESMO #ESMO26 @OncoAlert
Much anticipated ACTICCA-1
➡️adj cis/gem v cape #BTC
➡️mod ITT n=591
➡️no diff in DFS at 24mth 52% v 44%
RMST at 3 yrs ⬆️DFS by 2.6mth
➡️28% iCCA -no maj subgroup diff
➡️mOS 58.1 v 48.2 p=0.1
❎No change to std ?an option, NB need as backbone 1st line!
@myESMO @OncoAlert #ESMO26
Paclitaxel +\-tovecimig: COMPANION-002 ph2/3
➡️prev treated #BTC wo actionable alterations
➡️ORR 17.1 v5.3%; DCR 62 v 37%
➡️mPFS 4.7 v 2.6mths - benefits seen at PFS2 noting crossover
➡️OS not sig but nb crossover
@myESMO #ESMO26 @OncoAlert
MASTERPLAN randomised ph2
➡️chemo(90% mFFX) +\-SBRT localised #PDAC
➡️included potentially operable high risk /BR &LAPC not operable
➡️primary endpoint 12mth LRR :20% v 52%
➡️more R0 resections with SBRT
➡️mPFS 11.9 v6.3mth; mOS 22 v 14mth
@myesmo #ESMO26 @oncoalert
And we are 🚀 #ESMO26 🔝GI abstracts! 👇
🚨 #ESMO26 GI Cancer: Top Ten by @OncoAlert 🧬
From organ preservation in dMMR rectal and gastric cancer to RAS(ON) inhibition in pancreatic cancer and bispecifics in biliary tract cancer, our faculty picked the must-know GI abstracts from Madrid 👇
#GICancer #CRCSM
@CathyEngMD, @BenWestphalen, @graokane, @NiuSanford, @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @MarioBalsaMD, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara , @pashtoonkasi
, @GillSharlene
AMPLIFY-7P randomised ph2
✅7-valent(camupepimut) mKRAS lymph node targeted amphiphile
➡️curative intent & no recurrence <6mth #PDAC
✅T cell responses,primary endpt-ve
➡️benefit in ctDNA-ve& no rads?
➡️DFS @6mth benefit of 14% p=0.056
✅ph3 planned
@myESMO @OncoAlert #ESMO26
#LBA82 subgroup analysis RASolute 302 #PDAC
➡️HR for OS across subtypes 0.32-0.46
➡️G12R 0.61 (0.29-1.30)
➡️RAS WT numbers small (3%) but still OS benefit!
🤔perhaps ORR and mPFS not as pronounced in these populations!
✅std second line treatment
@myESMO #ESMO26 @OncoAlert
Grainne O'Kane retweeted
🚨 FDA NEWS |
AZUR 1 Update in #RectalCancer
FDA grants accelerated approval to dostarlimab (Jemperli) for previously untreated stage II/III dMMR/MSI-H locally advanced rectal cancer.First immunotherapy in this setting — may allow some patients to avoid chemo, radiation, and surgery.AZUR-1: 68% cCR12, 76% no evidence of disease ≥1 year, no recurrences in responders (median FU >2 yrs). Nearly ¾ of patients avoided surgery/RT/chemo
@CathyEngMD @BenWestphalen @graokane @NiuSanford @AndresC27622123 @GillSharlene @pashtoonkasi @DrVilmaPBarcia @Erman_Akkus @GIMedOnc @UOzkerim @MarioBalsaMD @p_ciracimd @DraMartinezLago @DaisukeKotani @Aiims1742 @ARosen380 @realbowtiedoc @KoheiShitara @GaiaGriguolo @scocmem
Grainne O'Kane retweeted
“It’s been a journey” Shroff told @NBCNews. “I’ve spent my entire life trying to eradicate cancer, primarily pancreatic cancer, but also liver cancers.”
nbcnews.com/health/disease/r…
An homage to Rachna Shroff, including thoughts from her family. Please read, share & honor her memory.
Grainne O'Kane retweeted
This week’s OncoAlert 🚨 Newsletter is OUT! Packed with the latest updates in oncology. subscribe here 👉 buff.ly/N5gYtAc
This week:
• MATTERHORN OS: periop durva + FLOT is the new SOC in gastric/GEJ
• FDA: tucatinib + HP maintenance in HER2+ MBC ( @ErikaHamilton9 )
• S1914: no benefit for atezo + SBRT in early NSCLC
• KEYNOTE-427, STAMINA, VIOLETTE & more
Free, weekly, by colleagues for colleagues 👇
@Uromigos, @matteolambe, @aftimosp, @EdeAzambuja, @DrSGraff, , @doublewhammied, @maryamlustberg, @raalbany, @hoperugo, @stolaney1, @LoiSher, @JaniceTNBCmets, @montypal, @DrDanielHeng, @apoloandrea, @DrChoueiri, @PGrivasMDPhD, @TiansterZhang, @neerajaiims, @amerseburger, @sonpavde, @drenriquegrande, @tompowles1, @cdanicas, @nataliagandur, @realbowtiedoc, @OncoCifu88, @scocmem, @FernandoOnco, @ElisaAgostinett, @tobeelizabeth, @ErmanAkkus, @MarioBalsaMD, @DrMirallas, @GIMedOnc, @UOzkerim, @DrRishabhOnco, @PaulJiL, @DaisukeKotani, @DraMartinezLago, @pciracimd, @BenWestphalen, @CentralParkWMD, @graokane, @AmandaNizamMD
Grainne O'Kane retweeted
The OncoAlert #ESMO26 PULSE Faculty is ready 🇪🇸
@cdanicas, @hoperugo, @DrChoueiri, @TiansterZhang, @matteolambe, @NiuSanford, @stolaney1, @christine_lovly, @amerseburger, @GlopesMd, @tompowles1, @montypal, @Icro_Meattini, @PGrivasMDPhD, @brian_rini, @CathyEngMD, @apolo_andrea, @AndreaNecchi, @DrSGraff, @Icro_Meattini, @BenWestphalen, @graokane, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @DrYukselUrun, @Lucarecco, @mzugman, @HHorinouchi, @p_ciracimd, @DraMartinezLago, @DrVilmaPBarcia, @GIMedOnc, @MarioBalsaMD, @scocmem, @AmandaNizamMD, @GaiaGriguolo, @JankovicK, @Dr_Oncologista, @Erman_Akkus @WeOncologists
Our faculty will report live from Madrid to keep you up to date on the science, whether you're there or at home. OncoAlert Has you Covered!!
Less noise. No nonsense. Just science.
Strictly By Colleagues... For Colleagues!

















































